CBP/Catenin antagonists for enhancing asymmetric division of somatic stem cells

US10092568B2 · kind B2 · utility

Assignee

• University of Southern California · US

Inventors

• Michael Kahn · Los Angeles, US
• Jia-Ling Teo · Altadena, US
• Michael McMillan · Alhambra, US
• Yi Zhao · South Pasadena, US
• Yongfeng Wu · San Gabriel, US

Key dates

• Filing date: May 15, 2013
• Grant date: Oct 9, 2018
• Expiry date: Sep 7, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are: methods for treating aging or an age-related condition, symptom or disease; methods for stimulating hair growth, regrowth or pigmentation (or preventing hair loss); methods for increasing the expression of an adenosine receptor in dermal cells (in combination with hair growth); methods for treating a condition or disease of the skin or at least one symptom thereof, including cosmetic treatment (e.g., wrinkles, hyperpigmentation, redness, rosacea, dryness, cracking, loss of firmness, loss of elasticity, thinning, and loss of vibrance). The methods comprise administering a sufficient amount of a CBP/catenin (e.g., CBP/β-catenin) antagonist as disclosed, and particularly wherein administration is in an amount and manner sufficient to provide for increasing the number of asymmetric renewing divisions relative to, or at the expense of symmetric divisions in relevant somatic stem cell population. In particular aspects, the CBP/catenin (e.g., CBP/β-catenin) antagonist comprises an alkyl and/or fatty acid ester derivative thereof as disclosed herein.